alexa
Reach Us +447480022765
Emerging Prognostic Biomarkers in Non Small Cell Lung Cancer Patients:Impact of Treatment with Nimesulide (COX-2 Inhibitor) Combined with Chemotherapy | Abstract
ISSN: 2161-105X

Journal of Pulmonary & Respiratory Medicine
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Emerging Prognostic Biomarkers in Non Small Cell Lung Cancer Patients:Impact of Treatment with Nimesulide (COX-2 Inhibitor) Combined with Chemotherapy

Soad M Abdel Ghany1, Nagla T El Melegy2, Aliae AR Mohamed-Hussein3* and Randa S Hana4

1Professor of Medical Biochemistry, Faculty of Medicine, Assiut University, Assiut, Egypt

2Professor of Medical Biochemistry, Faculty of Medicine, Assiut University, Assiut, Egypt

3Associate professor of pulmonology, Chest department, Assiut University, Assiut, Egypt

4Lecturer of Medical Biochemistry, Faculty of Medicine, Assiut University, Assiut, Egypt

*Corresponding Author:
Dr. Aliae AR Mohamed Hussein
Associate Professor of Pulmonology
Chest Department
Assiut University Hospitals
Assiut , Egypt
E-mail: [email protected]

Received date: November 14, 2011; Accepted date: Dececmber 16, 2011; Published date: Dececmber 18, 2011

Citation: Abdel Ghany SM, El Melegy NT, Mohamed-Hussein AAR, Hana RS (2011) Emerging Prognostic Biomarkers in Non Small Cell Lung Cancer Patients: Impact of Treatment with Nimesulide (COX-2 Inhibitor) Combined with Chemotherapy. J Pulmonar Respirat Med S5:003. doi:10.4172/2161-105X.S5-003

Copyright: © 2011 Abdel Ghany SM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

To date, the treatment outcome of non small cell lung cancer (NSCLC) is still not satisfactory and new treatment options are urgently needed. The present study was designed to: 1) evaluate the effects of the antiangiogenic drug; nimesulide (NSAID, a COX-2 inhibitor) combined with chemotherapy on NSCLC treatment progress, 2) Evaluate the role of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), as prognostic indicators in NSCLC, 3) Correlate the above parameters levels with the clinicopathological status of the patients during the therapy. The study included 30 NSCLC. The patients were divided to: group I, included 17 patients received chemotherapy alone and group II included 13 patients received the same chemotherapy with Nimesulide and 10 as controls. Serum and biopsies were taken for all subjects on admission and 3 weeks after the completion of treatment. Results: serum and tissue levels of VEGF and bFGF, were significantly higher in NSCLC patients and decreased significantly after treatment specially in group II compared to group I. The serum and tissue levels of the studied parameters decreased significantly in the responders as compared to resistant cases. The response rate after combined therapy was 69% versus 53% after chemotherapy alone. In conclusion, Nimesulide appears to boost the efficacy of the traditional chemotherapy as its co-administration showed encouraging effects on improving and normalization of the proangiogenic parameters levels and in turn the vascular supply of tumors. This may have good impact on the patient outcome, prolongation of their survival rate and prognosis.

Keywords

Recommended Conferences
Share This Page
Top